Ignite Creation Date:
2025-12-25 @ 1:09 AM
Ignite Modification Date:
2025-12-25 @ 11:20 PM
Study NCT ID:
NCT03552393
Status:
COMPLETED
Last Update Posted:
2022-03-07
First Post:
2018-04-27
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-08-03
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-19
Completion Date Type:
ACTUAL
First Submit Date:
2018-04-27
First Submit QC Date:
None
Study First Post Date:
2018-06-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-01-18
Results First Submit QC Date:
None
Results First Post Date:
2022-03-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-03
Last Update Post Date:
2022-03-07
Last Update Post Date Type:
ACTUAL